Works matching IS 03407004 AND DT 2022 AND VI 71 AND IP 8
Results: 20
Vaccination against galectin-1 promotes cytotoxic T-cell infiltration in melanoma and reduces tumor burden.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 2029, doi. 10.1007/s00262-021-03139-4
- By:
- Publication type:
- Article
Oral administration of a whole glucan particle (WGP)-based therapeutic cancer vaccine targeting macrophages inhibits tumor growth.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 2007, doi. 10.1007/s00262-021-03136-7
- By:
- Publication type:
- Article
Local radiotherapy and E7 RNA-LPX vaccination show enhanced therapeutic efficacy in preclinical models of HPV16<sup>+</sup> cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1975, doi. 10.1007/s00262-021-03134-9
- By:
- Publication type:
- Article
Immune-related adverse events of COVID-19 vaccination in skin cancer patients receiving immune-checkpoint inhibitor treatment.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 2051, doi. 10.1007/s00262-021-03133-w
- By:
- Publication type:
- Article
Efficacy of immunotherapy beyond RECIST progression in advanced melanoma: a real-world evidence.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1949, doi. 10.1007/s00262-021-03132-x
- By:
- Publication type:
- Article
Pediatric glioblastoma: mechanisms of immune evasion and potential therapeutic opportunities.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1813, doi. 10.1007/s00262-021-03131-y
- By:
- Publication type:
- Article
Efficacy of an ALDH peptide-based dendritic cell vaccine targeting cancer stem cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1959, doi. 10.1007/s00262-021-03129-6
- By:
- Publication type:
- Article
Associations between immune-related thyroid dysfunction and efficacy of immune checkpoint inhibitors: a systematic review and meta-analysis.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1795, doi. 10.1007/s00262-021-03128-7
- By:
- Publication type:
- Article
Alterations of circulating lymphocyte subsets in patients with colorectal carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1937, doi. 10.1007/s00262-021-03127-8
- By:
- Publication type:
- Article
Hypoxia-inducible factor-1 alpha expression is induced by IL-2 via the PI3K/mTOR pathway in hypoxic NK cells and supports effector functions in NKL cells and ex vivo expanded NK cells.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1989, doi. 10.1007/s00262-021-03126-9
- By:
- Publication type:
- Article
Functional virus-specific memory T cells survey glioblastoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1863, doi. 10.1007/s00262-021-03125-w
- By:
- Publication type:
- Article
Selection of antibody and light exposure regimens alters therapeutic effects of EGFR-targeted near-infrared photoimmunotherapy.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1877, doi. 10.1007/s00262-021-03124-x
- By:
- Publication type:
- Article
Prognostic value, DNA variation and immunologic features of a tertiary lymphoid structure-related chemokine signature in clear cell renal cell carcinoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1923, doi. 10.1007/s00262-021-03123-y
- By:
- Publication type:
- Article
A phase I dose-escalation, safety/tolerability, and preliminary efficacy study of the intratumoral administration of GEN0101 in patients with advanced melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 2041, doi. 10.1007/s00262-021-03122-z
- By:
- Publication type:
- Article
A real-world study of the efficacy and safety of anti-PD-1 antibodies plus lenvatinib in patients with advanced gallbladder cancer.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1889, doi. 10.1007/s00262-021-03121-0
- By:
- Publication type:
- Article
Blocking GARP-mediated activation of TGF-β1 did not alter innate or adaptive immune responses to bacterial infection or protein immunization in mice.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1851, doi. 10.1007/s00262-021-03119-8
- By:
- Publication type:
- Article
Novel inhibitor of hematopoietic cell kinase as a potential therapeutic agent for acute myeloid leukemia.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1909, doi. 10.1007/s00262-021-03111-2
- By:
- Publication type:
- Article
The integration of systemic and tumor PD-L1 as a predictive biomarker of clinical outcomes in patients with advanced NSCLC treated with PD-(L)1blockade agents.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1823, doi. 10.1007/s00262-021-03107-y
- By:
- Publication type:
- Article
Safety, antitumor activity and biomarkers of sugemalimab in Chinese patients with advanced solid tumors or lymphomas: results from the first-in-human phase 1 trial.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1897, doi. 10.1007/s00262-021-03102-3
- By:
- Publication type:
- Article
Combination immunotherapy including OncoVEX<sup>mGMCSF</sup> creates a favorable tumor immune micro-environment in transgenic BRAF murine melanoma.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 8, p. 1837, doi. 10.1007/s00262-021-03088-y
- By:
- Publication type:
- Article